SEATTLE, WA / ACCESS Newswire / May 6, 2026 / Aptevo Therapeutics Inc. (Nasdaq:APVO) today reported new clinical results from its RAINIER frontline acute myeloid leukemia (AML) trial. The Company is ...
Scientists from the German Cancer Research Center (DKFZ) and the HI-STEM* Stem Cell Institute have deciphered a key mechanism ...
Azacitidine-venetoclax showed superior event-free survival and overall response rates compared to traditional induction chemotherapy in AML patients. The study highlighted reduced hospital stays, ...
SELLAS Life Sciences reports successful Phase 2 trial results for SLS009 in relapsed/refractory AML, exceeding response and survival rates. SELLAS Life Sciences Group has announced that its Phase 2 ...
CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Syros Pharmaceuticals (NASDAQ:SYRS), a biopharmaceutical company committed to advancing new standards of care for the frontline treatment of hematologic ...
Panelists emphasize that patients with KMT2A-rearranged acute myeloid leukemia (AML) often face steep educational challenges at diagnosis, requiring clear communication about the subtype’s ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results